Merus BV, of Utrecht, the Netherlands, filed an F-1 seeking to raise up to $60 million in a U.S. IPO. The company, which raised $80.5 million in a series C round earlier this year to support its bispecific antibody approach in immuno-oncology, is seeking to list on Nasdaq under the ticker MRUS.